H.C. Wainwright lowered the firm’s price target on Travere Therapeutics to $32 from $35 and keeps a Buy rating on the shares. Following Travere’s Q2 report, the firm changed its model to remove the revenue stream from the bile acid products after Q3, adjust future operating expenses to reflect current spend for the Filspari launch as well as the removal of ongoing investment related to the former bile acid portfolio and add potential milestone payments of up to $235M from Mirum, adjusted for what it estimates to be 40% odds of success.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics reports Q2 EPS ($1.13), consensus ($1.16)
- Travere Therapeutics Reports Second Quarter 2023 Financial Results
- J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks — Including One With 90% Upside Potential
- Travere Therapeutics initiated with an Overweight at JPMorgan
- Travere Therapeutics to Report Second Quarter 2023 Financial Results